Vaccination with a DNA vaccine based on human PSCA and HSP70 adjuvant enhances the antigen-specific CD8+ T-cell response and inhibits the PSCA+ tumors growth in mice

Journal of Gene Medicine

Volumn 9, Issue 8, 2007, Pages 715-726

  Zhang, Xiaopeng ^a   Yu, Changming ^a   Zhao, Jian ^a   Fu, Ling ^a   Yi, Shaoqiong ^a   Liu, Shuling ^a   Yu, Ting ^a   Chen, Wei ^a  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

Author keywords

Adjuvant; DNA vaccine; HSP70; Prostate cancer; PSCA

Indexed keywords

DNA VACCINE; EPITOPE; HEAT SHOCK PROTEIN 70; PLASMID DNA; PROSTATE STEM CELL ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENCY; DRUG TARGETING; IMMUNE RESPONSE; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MALE; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; SPLEEN CELL; TH1 CELL; TH2 CELL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CELL PROLIFERATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HSP70 HEAT-SHOCK PROTEINS; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; NEOPLASM PROTEINS; PLASMIDS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; VACCINATION; VACCINES, DNA;

MUS;

EID: 34548059162     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1067     Document Type: Article

References (54)

1. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer 2001; 37(Suppl 8): S4-66.
2. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005; 55: 10-30.
3. Hodge JW, Schlom J, Donohue SJ, et al. A recombinant vaccinia virus expressing human prostate-specific antigen (PSA): safety and immunogenicity in a non-human primate. Int J Cancer 1995; 63: 231-237.
4. Kim JJ, Trivedi NN, Wilson DM, et al. Molecular and immunological analysis of genetic prostate specific antigen (PSA) vaccine. Oncogene 1998; 17: 3125-3135.
5. Fong L, Ruegg CL, Brockstedt D, et al. Induction of tissue-specific autoimmune prostatitis with prostatic acid phosphatase immunization: implications for immunotherapy of prostate cancer. J Immunol 1997; 159: 3113-3117.
6. Saffran DC, Reiter RE, Jakobovits A, et al. Target antigens for prostate cancer inummotherapy. Cancer Metastasis Rev 1999; 18: 437-449.
7. Zhang S, Zhang HS, Reuter VE, et al. Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers. Clin Cancer Res 1998; 4: 295-302.
8. Murphy GP, Tjoa BA, Simmons SJ, et al. Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease. The Prostate 1999; 38: 73-78.
9. Murphy G, Tjoa B, Ragde H, et al. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate 1996; 29: 371-380.
10. Eder JP, Kantoff PW, Roper K, et al. A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin Cancer Res 2000; 6: 1632-1638.
11. Pavlenko M, Roos AK, Lundqvist A, et al. A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer. Br J Cancer 2004; 91: 688-694.
12. Reiter RE, Gu Z, Watabe T, et al. Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci USA 1998; 95: 1735-1740.
13. Amara N, Palapattu GS, Schrage M, et al. Prostate stem cell antigen is overexpressed in human transitional cell carcinoma. Cancer Res 2001; 61: 4660-4665.
14. Argani P, Rosty C, Reiter RE, et al. Discovery of new markers of cancer through serial analysis of gene expression: prostate stem cell antigen is overexpressed in pancreatic adenocarcinoma. Cancer Res 2001; 61: 4320-4324.
15. Gu Z, Thomas G, Yamashiro J, et al. Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene 2000; 19: 1288-1296.
16. Saffran DC, Raitano AB, Hubert RS, et al. Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts. Proc Natl Acad Sci U S A 2001; 98: 2658-2663.
17. Ulmer JB, Donnelly JJ, Parker SE, et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993; 259: 1745-1749.
18. Facer CA, Tanner M. Clinical trials of malaria vaccines: progress and prospects. Adv Parasitol 1997; 39: 1-68.
19. Boyer JD, Chattergoon M, Shah A, et al. HIV-1 DNA based vaccine induces a CD8 mediated cross-clade CTL response. Developments Biol Standardization 1998; 95: 147-153.
20. MacGregor RR, Boyer JD, Ugen KE, et al. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. J Infect Dis 1998; 178: 92-100.
21. Schleef M, Schorr J. Plasmid DNA for clinical phase I and II studies. Large-scale cGMP manufacturing and quality assurance. Adv Exp Med Biol 1998; 451: 481-486.
22. Doolan DL, Hoffman SL. DNA-based vaccines against malaria: status and promise of the Multi-Stage Malaria DNA Vaccine Operation. Int J Parasitol 2001; 31: 753-762.
23. Zheng J, Zhang FP, Si LS, et al. [Preliminary study of HPV16 L1/ E6-E7 chimeric recombinant DNA vaccine plasmid construction and expression in CHO cell]. Chinese J Exp Clin Virol 2003; 17: 66-69.
24. Vastag B. Ebola vaccines tested in humans, monkeys. J Am Med Assn 2004; 291: 549-550.
25. MacGregor RR, Boyer JD, Ugen RE, et al. Plasmid vaccination of stable HIV-positive subjects on antiviral treatment results in enhanced CD8 T-cell immunity and increased control of viral "blips". Vaccine 2005; 23: 2066-2073.
26. Webster DP, Dunachie S, Vuola JM, et al. Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. Proc Natl Acad Sci U S A 2005; 102: 4836-4841.
27. Blachere NE, Srivastava PK. Heat shock protein-based cancer vaccines and related thoughts on immunogenicity of human tumors. Semin Cancer Biol 1995; 6: 349-355.
28. Srivastava PK, Udono H, Blachere NE, et al. Heat shock proteins transfer peptides during antigen processing and CTL priming. Immunogenetics 1994; 39: 93-98.
29. Srivastava PK, Udono H. Heat shock protein-peptide complexes in cancer immunotherapy. Curr Opin Immunol 1994; 6: 728-732.
30. Hightower LE. Heat shock, stress proteins, chaperones, and proteotoxicity. Cell 1991; 66: 191-197.
31. Srivastava PK. Heat shock proteins in immune response to cancer: the Fourth Paradigm. Experientia 1994; 50: 1054-1060.
32. Blachere NE, Udono H, Janetzki S, et al. Heat shock protein vaccines against cancer. J Immunother 1993; 14: 352-356.
33. Srivastava PK, Heike M. Tumor-specific immunogenicity of stress-induced proteins: convergence of two evolutionary pathways of antigen presentation? Semin Immunol 1991; 3: 57-64.
34. Srivastava PK, DeLeo AB, Old LJ. Tumor rejection antigens of chemically induced sarcomas of inbred mice. Proc Natl Acad Sci U S A 1986; 83: 3407-3411.
35. Blachere NE, Li Z, Chandawarkar RY, et al. Heat shock protein-peptide complexes, reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocyte response and tumor immunity. J Exp Med 1997; 186: 1315-1322.
36. Chen CH, Wang TL, Hung CF, et al. Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer Res 2000; 60: 1035-1042.
37. Hauser H, Shen L, Gu QL, et al. Secretary heat-shock protein as a dendritic cell-targeting molecule: a new strategy to enhance the potency of genetic vaccines. Gene Ther 2004; 11: 924-932.
38. Qazi KR, Wikman M, Vasconcelos NM, et al. Enhancement of DNA vaccine potency by linkage of Plasmodium falciparum malarial antigen gene fused with a fragment of HSP70 gene. Vaccine 2005; 23: 1114-1125.
39. Pavlenko M, Roos AK, Leder C, et al. Comparison of PSA-specific CD8+ CTL responses and antitumor immunity generated by plasmid DNA vaccines encoding PSA-HSP chimeric proteins. Cancer Immunol Immunother 2004; 53: 1085-1092.
40. Fynan EF, Webster RG, Fuller DH, et al. DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc Natl Acad Sci U S A 1993; 90: 11478-11482.
41. Guan P, Doytchinova IA, Zygouri C, et al. MHCPred: bringing a quantitative dimension to the online prediction of MHC binding. Appl Bioinform 2003; 2: 63-66.
42. Guan P, Doytchinova IA, Zygouri C, et al. MHCPred: a server for quantitative prediction of peptide-MHC binding. Nucleic Acids Res 2003; 31: 3621-3624.
43. Reche PA, Glutting JP, Zhang H, et al. Enhancement to the RANKPEP resource for the prediction of peptide binding to MHC molecules using profiles. Immunogenetics 2004; 56: 405-419.
44. Bhasin M, Raghava GP. Prediction of promiscuous and high-affinity mutated MHC binders. Hybridoma Hybridomics 2003; 22: 229-234.
45. Hou LH, Du Y, Zhang XP, et al. [Expression of prostate stem cell antigen (PSCA) and selection of its specific binding peptide]. Sheng Wu Gong Cheng Xue Bao 2004; 20: 694-698.
46. Matsueda S, Kobayashi K, Nonaka Y, et al. Identification of new prostate stem cell antigen-derived peptides immunogenic in HLA-A2(+) patients with hormone-refractory prostate cancer. Cancer Immunol Immunother 2004; 53: 479-489.
47. Dannull J, Diener PA, Prikler L, et al. Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer. Cancer Res 2000; 60: 5522-5528.
48. Gu Z, Yamashiro J, Kono E, et al. Anti-prostate stem cell antigen monoclonal antibody 1G8 induces cell death in vitro and inhibits tumor growth in vivo via a Fc-independent mechanism. Cancer Res 2005; 65: 9495-9500.
49. Ueda G, Tamura Y, Hirai I, et al. Tumor-derived heat shock protein 70-pulsed dendritic cells elicit tumor-specific cytotoxic T lymphocytes (CTLs) and tumor immunity. Cancer Sci 2004; 95: 248-253.
50. Haug M, Dannecker L, Schepp CP, et al. The heat shock protein Hsp70 enhances antigen-spedfic proliferation of human CD4+ memory T cells. Eur J Immunol 2005; 35: 3163-3172.
51. Radcliffe JN, Roddick JS, Friedmann PS, et al. Prime-boost with alternating DNA vaccines designed to engage different antigen presentation pathways generates high frequencies of peptide-specific CD8+ T cells. J Immunol 2006; 177: 6626-6633.
52. More SH, Breloer M, von Bonin A. Eukaryotic heat shock proteins as molecular links in innate and adaptive immune responses: Hsp60-mediated activation of cytotoxic T cells. Int Immunol 2001; 13: 1121-1127.
53. Breloer M, Dorner B, More SH, et al. Heat shock proteins as "danger signals": eukaryotic Hsp60 enhances and accelerates antigen-specific IFN-gamma production in T cells. Eur J Immunol 2001; 31: 2051-2059.
54. King CA, Spellerberg MB, Zhu D, et al. DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma. Nat Med 1998; 4: 1281-1286.